Cargando…
Biomarkers in active surveillance
The use of active surveillance (AS) is increasing for favorable-risk prostate cancer. However, there remain challenges in patient selection for AS, due to the limitations of current clinical staging. In addition, monitoring protocols relying on serial biopsies is invasive and presents risks such as...
Autores principales: | Loeb, Stacy, Tosoian, Jeffrey J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861276/ https://www.ncbi.nlm.nih.gov/pubmed/29594029 http://dx.doi.org/10.21037/tau.2017.12.26 |
Ejemplares similares
-
PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer
por: Tosoian, Jeffrey, et al.
Publicado: (2010) -
Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions
por: Eyrich, Nicholas W., et al.
Publicado: (2021) -
PTEN Status Assessment in the Johns Hopkins Active Surveillance Cohort
por: Tosoian, Jeffrey J., et al.
Publicado: (2018) -
Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
por: Andreas, Darian, et al.
Publicado: (2016) -
Factors that influence clinicians’ decisions to decrease active surveillance monitoring frequency or transition to watchful waiting for localised prostate cancer: a qualitative study
por: Lowenstein, Lisa M, et al.
Publicado: (2021)